Entity
National Blood Authority
+$327m (+15.3%) on 2025-26 estimated actual
Kind of expense
Traced to named suppliers and grant recipients
$293m falls in 2026-27, equal to 11.9% of this total: $292m in contracts and $875k in grants. estimate: annualised
From AusTender contract notices and GrantConnect grant awards published since 2022-07-01. Each contract’s or grant’s value is spread evenly from its start to end date. These values are commitments, not payments, and records published before 2022-07-01 are not included yet.
By program
| Program | 2025-26 estimated actual |
2026-27 Budget estimate |
Change | Share | Removed |
|---|---|---|---|---|---|
| Program 1.1: National Blood Agreement ManagementThe National Blood Authority is a material statutory entity that manages and coordinates arrangements for the supply of… | $2.1bn | $2.5bn | +$327m +15.3% | 100.0% | – |
Worth a closer look
Patterns in this agency’s contract notices published in 2025-26 and 2026-27 to date. Each is a measurable pattern with common legitimate explanations; none is a finding of wrongdoing. How these are defined.
- Value increased after award 1 contract · $2.4m
The contract’s value rose after it was first published. - Published long after it started 6 contracts · $10m
The contract notice was published more than six months after the contract’s start date.
Who gets paid
Contracts active in 2026-27, from AusTender. Amounts for the year are each contract’s value spread across its term. estimate: annualised
- Contracts active
- 79
- Suppliers
- 66
- Limited tender
- 75.5% of value · 29 contracts
- Value added by amendments
- $141m across 31 amended contracts
Largest suppliers
Suppliers who are individuals are counted in the totals above but not listed. Why
| Supplier | Contracts | 2026-27 est. | Limited tender |
|---|---|---|---|
| Roche Products Pty Ltd | 1 | $106m | 100.0% |
| CSL BEHRING (AUSTRALIA) PTY LTD | 3 | $83m | 70.6% |
| Novo Nordisk Pharmaceuticals Pty Ltd | 1 | $38m | 100.0% |
| SANOFI-AVENTIS AUSTRALIA PTY LTD | 1 | $27m | 0.0% |
| Takeda Pharmaceuticals Australia Pty Ltd | 2 | $13m | 44.8% |
| Pfizer Australia Pty Ltd | 1 | $4.4m | 0.0% |
| PARAGON CARE GROUP AUSTRALIA PTY LTD [525] | 1 | $3.9m | 100.0% |
| BIO-RAD LABORATORIES PTY LTD | 1 | $2.7m | 100.0% |
| Informatech Pty Ltd | 1 | $2.1m | 0.0% |
| Australian Haemophilia Centre Directors' Organisation Inc | 1 | $1.7m | 100.0% |
| South Australian Department for Health and Wellbeing | 1 | $1.3m | 100.0% |
| Data#3 Limited Formerly: Data #3 Business | 2 | $840k | 0.0% |
| ORTHO-CLINICAL DIAGNOSTICS AUSTRALI | 1 | $778k | 100.0% |
| Aspex Consulting | 2 | $652k | 0.0% |
| Knox IT Pty Ltd | 2 | $550k | 0.0% |
Largest contracts
Suppliers who are individuals are counted in the totals above but not listed. Why
Professional services by kind of work
Contracts active in 2026-27 that AusTender files under “management and business professionals”, sorted by an AI model reading each contract’s description. AI-classified estimate: annualised
In 2024-25 the entity reported paying $281k on consultancy contracts (cash, including GST). Contracts classified as consultancy come to $541k for that year (AusTender values spread over each contract’s term). The two are measured differently, so they are not expected to match. How we classify.
Grants awarded
Grants active in 2026-27, from GrantConnect. Each grant’s total value is spread across its term. estimate: annualised
- Grants active
- 10
- 2026-27 est.
- $875k
- Recipients
- 8
- Without an open round
- 24.8% of value
By category
Largest recipients
Recipients who are individuals, and awards that name no single recipient, are counted above but not listed. Why
| Recipient | Grants | 2026-27 est. |
|---|---|---|
| Monash University | 3 | $246k |
| Haemophilia Foundation Australia Inc | 1 | $217k |
| The University of Western Australia | 1 | $115k |
| The George Institute for Global Health | 1 | $73k |
| Australian National University | 1 | $68k |
| Royal Brisbane and Women's Hospital Foundation | 1 | $64k |
| Menzies School of Health Research | 1 | $54k |
| Adelaide University | 1 | $39k |
Contract spending reported by the entity
What the entity reported in its annual reports, from the Transparency Portal: cash paid in each year, including GST. These are actual payments, unlike the AusTender contract values above. They are shown as published and are not used in any total on this site. reported
| Year | Consultancy | Other contracts |
|---|---|---|
| 2024-25 | $281k 2 contracts |
$1.9bn 60 contracts |
| 2023-24 | $674k 7 contracts |
$1.9bn 77 contracts |
| 2022-23 | $1.4m 6 contracts |
$1.7bn 57 contracts |
| 2021-22 | $1.2m 10 contracts |
$1.6bn 67 contracts |
Organisations paid the most in 2024-25
As listed by the entity, usually its five largest of each type. Organisations who are individuals are not listed. Why
| Consultancy | 2024-25 |
|---|---|
| HealthConsult Pty Ltd | $200m looks wrong |
| KPMG | $82m looks wrong |
| Other contracts | 2024-25 |
|---|---|
| Australian Red Cross Lifeblood | $857.6bn looks wrong |
| CSL Behring (Australia) Pty Ltd | $687.2bn looks wrong |
| Grifols Australia Pty Ltd | $108.3bn looks wrong |
| Roche Products Pty Ltd | $63.6bn looks wrong |
| Takeda Pharmaceuticals Australia Pty Ltd | $59.8bn looks wrong |
- Larger than the entity’s reported total for the year ($281k).
- More than twice the entity’s largest yearly total expenses in the Budget papers ($2.9bn). It may have been entered in dollars instead of thousands.